Novavax (XSWX:NVAX) 1-Year Sharpe Ratio: N/A (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:NVAX Novavax Inc XSWX:NVAX
46 GF Score
Price CHF7.24
GF Value CHF2.58
! 6 Warning Signs
View Full Analysis

What is Novavax 1-Year Sharpe Ratio?

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-08-22), Novavax's 1-Year Sharpe Ratio is Not available.

Novavax  (XSWX:NVAX) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Novavax 1-Year Sharpe Ratio Related Terms

XSWX:NVAX vs JBIO, AVLN, TRAX: 1-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, Novavax's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novavax 1-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Novavax's 1-Year Sharpe Ratio falls into.


XSWX:NVAX
46GF Score
Novavax Inc XSWX:NVAX
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Is Novavax (XSWX:NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of CHF7.24 is trading 180.7% above its estimated GF Value™ of CHF2.58.

Key valuation signals for XSWX:NVAX:

  • 1-Year Sharpe Ratio: N/A
  • GF Value™: CHF2.58 vs. price of CHF7.24 (180.7% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the XSWX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
46GF Score

Get the complete analysis for XSWX:NVAX

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF7.24
Price
CHF2.58
GF Value